EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Meibomian Gland Loss and Dysfunction in Mild versus Moderate-Severe Thyroid Eye Disease

Hossein Aghaei, Fatemeh Zarastvand, Parya Abdolalizadeh, Nasser Karimi, Acieh Es’haghi, Jeremy D. Clark, Christopher J. Compton, Nicole L. West, Mohsen Bahmani Kashkouli

Journal of Current Ophthalmology · 2024-04 · 36 (2) · 145-151

DOI: 10.4103/joco.joco_176_23 ↗
AbstractBibliografische Angaben

Abstract

Abstract Purpose: To compare meibomian gland (MG) loss and MG dysfunction (MGD) in patients with mild versus moderate-severe thyroid eye disease (TED). Methods: Consecutive patients with TED and no other causes of dry eye disease underwent meibography and meiboscore of each eyelid were graded as 0 (no MG loss), 1 (66% loss), with a total score of 0–6. MG expression score (0–3), eyelid margin signs of MGD, lipid layer thickness (LLT), ocular surface disease index (OSDI), tear secretion, noninvasive tear break-up time (NITBUT), and tear meniscus height (TMH) were also assessed by a masked observer. Results: Included were 21 eyes (21 patients) with mild and 19 eyes (19 patients) with moderate-severe TED. The two groups were not different except for a higher frequency of smoking ( P < 0.01). Eyes with moderate-severe TED showed a higher upper eyelid meiboscore ( P = 0.03), MG expression score ( P < 0.01), and tear film osmolality ( P = 0.02) as well as lower LLT ( P = 0.03). Total meiboscore had a significantly positive correlation with OSDI (r s = 0.37) and tear film osmolality (r s = 0.50) as well as a negative correlation with NITBUT (r s = −0.55), TMH (r s = −0.44), and LLT (r s = −0.38). While older age, male gender, smoking, and longer duration of disease were significantly associated with the higher (≥3) meiboscore in univariate analysis, none remained significant in multivariate analysis. Conclusion: MG loss and MGD were significantly more severe in moderate-severe than mild TED.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →